We have an updated report [Version - 2023] available. Kindly sign up to get the sample of the report.
all report title image
  • Published In : Oct 2022
  • Code : CMI1713
  • Pages : 206
  • Formats :
      Excel and PDF
  • Industry : Pharmaceutical
Ingographics Image

Chronic kidney disease is a condition which is characterized by gradual loss of kidney function over time. Chronic kidney disease is also known as chronic renal disease. The kidney disease gets worse, wastes can build to high levels in your blood; other problems associated to chronic kidney disease are high blood pressure, a low red blood cell count, weak bones, poor nutrition, and nerve damage.

The main causes of chronic kidney disease include diabetes, hypertension, chronic glomerulonephritis, chronic pyelonephritis, chronic use of anti-inflammatory medication, autoimmune diseases, polycystic kidney disease, Alport disease, congenital malformations, and prolonged acute renal disease.

Market Dynamics

Key players in market are focused on gaining approvals from regulatory bodies, which is expected to drive the market growth over the forecast period. For instance, in September 2020, Ardelyx, Inc., a biopharmaceutical company focused on developing first-in-class medicines to improve treatment for people with kidney and cardiovascular diseases, announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) of tenapanor for the control of serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis.

Factors such as awareness initiatives by government bodies, increasing prevalence of chronic kidney disease, and product launches are driving the global chronic kidney disease drugs market growth. For instance, according to an article published by Centers for Disease Control and Prevention in 2021, more than 1 in 7, that is 15% of the U.S. adults or 37 million people, are estimated to have chronic kidney disease. According to same source, chronic kidney disease is more common in people aged 65 years or older (38%) than in people aged 45-64 years (12%) or 18-44 years.       

Key features of the study:

  • This report provides an in-depth analysis of the global chronic kidney disease drugs market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global chronic kidney disease drugs market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Sanofi, AstraZeneca plc., Amgen, Inc., Regeneron Pharmaceuticals, Inc., AbbVie Inc., ProKidney Corp., Pfizer, Inc., Bayer AG, F. Hoffmann-La Roche AG, Kissei Pharmaceutical Co., Ltd., Reata Pharmaceuticals, Inc., GlaxoSmithKline plc., Ardelyx, Inc., Boehringer Ingelheim International GmbH, Novo Nordisk A/S, Novartis AG, Johnson & Johnson, Astellas Pharma Inc., Takeda Pharmaceutical Company Limited, Jiangsu Hansoh Pharmaceutical Group Co., Ltd., Kibow Biotech, Inc., FibroGen, Inc., Cara Therapeutics, Pieris Pharmaceuticals, Inc., Mitsubishi Chemical Group Corporation, Pharmacosmos A/S., OPKO Health, Inc., Covis Pharma, Tricida, Inc., Eli Lilly and Company, Biosidus S.A., Teva Pharmaceutical Industries Ltd., YUHAN, Caladrius Biosciences, Inc., UnicoCell Biomed CO. LTD, Akebia Therapeutics, Inc., Allena Pharmaceuticals, and KBP Biosciences Co., Ltd.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global chronic kidney disease drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global chronic kidney disease drugs market.

Detailed Segmentation:

  • Global Chronic Kidney Disease Drugs Market, By Drug Class:
    • ACE Inhibitors
    • Angiotensin Receptor Blockers (ARBs)
    • B-Blockers
    • Calcium Channel Blockers
    • Loop Diuretics
    • Erythropoiesis-Stimulating Agents (ESAs)
    • Phosphate Binders
    • Others
  • Global Chronic Kidney Disease Drugs Market, By Route of Administration:
    • Oral
    • Subcutaneous
    • Intravenous
  • Global Chronic Kidney Disease Drugs Market, By Patient Type:
    • Dialysis
    • Others
  • Global Chronic Kidney Disease Drugs Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies 
    • Online Pharmacies
  • Global Chronic Kidney Disease Drugs Market, By Region:
    • North America
      • By Country
        • U.S.
        • Canada
    • Latin America
      • By Country
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Country
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Country
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Country
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Region/Country
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Sanofi*
      • Company Highlights
      • Products Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • AstraZeneca plc.
    • Amgen, Inc.
    • Regeneron Pharmaceuticals, Inc.
    • AbbVie Inc.
    • ProKidney Corp.
    • Pfizer, Inc.
    • Bayer AG
    • Hoffmann-La Roche AG
    • Kissei Pharmaceutical Co., Ltd.
    • Reata Pharmaceuticals, Inc.
    • GlaxoSmithKline plc
    • Ardelyx, Inc.
    • Boehringer Ingelheim International GmbH
    • Novo Nordisk A/S
    • Novartis AG
    • Johnson & Johnson
    • Astellas Pharma Inc.
    • Takeda Pharmaceutical Company Limited
    • Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
    • Kibow Biotech, Inc.
    • FibroGen, Inc.
    • Cara Therapeutics
    • Pieris Pharmaceuticals, Inc.
    • Mitsubishi Chemical Group Corporation
    • Pharmacosmos A/S
    • OPKO Health, Inc.
    • Covis Pharma
    • Tricida, Inc.
    • Eli Lilly and Company
    • Biosidus S.A.
    • Teva Pharmaceutical Industries Ltd.
    • YUHAN
    • Caladrius Biosciences, Inc.
    • UnicoCell Biomed CO. LTD
    • Akebia Therapeutics, Inc.
    • Allena Pharmaceuticals
    • KBP Biosciences Co., Ltd.

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snapshot, By Drug Class
      • Market Snapshot, By Route Of Administration
      • Market Snapshot, By Patient Type
      • Market Snapshot, By Distribution Channel
      • Market Snapshot, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Regulatory Scenario
    • Key Highlights
    • Research and Development
    • Collaboration, Mergers, and Acquisitions Scenario
    • Key Development
    • Recent Product Approvals and Launches
    • PEST Analysis
    • Pipeline Analysis
    • Epidemiology
  4. Global Chronic Kidney Disease Drugs Market- Impact of Coronavirus (Covid-19) Pandemic
    • COVID-19 Impact on the market
    • Impact on Global Chronic Kidney Disease Drugs Market
    • Impact on Clinical Trials
  5. Global Chronic Kidney Disease Drugs Market, By Drug Class, 2017 – 2030, (US$ Million)
    • Overview
      • Market Share Analysis, 2022 and 2030 (%)
      • Y-o-Y Growth Analysis, 2017 – 2030
      • Segment Trends
    • ACE Inhibitors
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
    • Angiotensin Receptor Blockers (ARBs)
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
    • B-Blockers
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
    • Calcium Channel Blockers
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
    • Loop Diuretics
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
    • Erythropoiesis-Stimulating Agents (ESAs)
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
    • Phosphate Binders
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
    • Others
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
  6. Global Chronic Kidney Disease Drugs Market, By Route Of Administration, 2017 – 2030, (US$ Million)
    • Overview
      • Market Share Analysis, 2022 and 2030 (%)
      • Y-o-Y Growth Analysis, 2017 – 2030
      • Segment Trends
    • Oral
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
    • Subcutaneous
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
    • Intravenous
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
  7. Global Chronic Kidney Disease Drugs Market, By Patient Type, 2017 – 2030, (US$ Million)
    • Overview
      • Market Share Analysis, 2022 and 2030 (%)
      • Y-o-Y Growth Analysis, 2017 – 2030
      • Segment Trends
    • Dialysis
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
    • Others
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
  8. Global Chronic Kidney Disease Drugs Market, By Distribution Channel, 2017 – 2030, (US$ Million)
    • Overview
      • Market Share Analysis, 2022 and 2030 (%)
      • Y-o-Y Growth Analysis, 2017 – 2030
      • Segment Trends
    • Hospital Pharmacies
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
    • Retail Pharmacies
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
    • Online Pharmacies
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
  9. Global Chronic Kidney Disease Drugs Market, By Region, 2017 – 2030, (US$ Million)
    • Introduction
      • Market Share Analysis, By Region, 2022 and 2030 (%)
      • Y-o-Y Growth Analysis, For Regions, 2017–2030
      • Regional Trends
    • North America
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Patient Type  2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million)
        • U.S.
        • Canada
    • Latin America
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Patient Type  2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Patient Type  2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million)
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Patient Type  2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million)
        • China
        • India
        • Japan
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Middle East
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Patient Type  2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Patient Type  2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million)
        • North Africa
        • Central Africa
        • South Africa
  10. Competitive Landscape
    • Heat Map Analysis
    • Company Profiles
      • Sanofi
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Market Strategies
      • AstraZeneca plc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Amgen, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Regeneron Pharmaceuticals, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • AbbVie Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • ProKidney Corp.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Pfizer, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Bayer AG
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • F. Hoffmann-La Roche AG
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Kissei Pharmaceutical Co., Ltd.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Reata Pharmaceuticals, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • GlaxoSmithKline plc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Ardelyx, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Boehringer Ingelheim International GmbH
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Novo Nordisk A/S
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Novartis AG
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Johnson & Johnson
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Astellas Pharma Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Takeda Pharmaceutical Company Limited
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Kibow Biotech, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • FibroGen, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Cara Therapeutics
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Pieris Pharmaceuticals, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Mitsubishi Chemical Group Corporation
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Pharmacosmos A/S
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • OPKO Health, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Covis Pharma
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Tricida, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Eli Lilly and Company
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Biosidus S.A.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Teva Pharmaceutical Industries Ltd.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • YUHAN
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Caladrius Biosciences, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • UnicoCell Biomed CO. LTD.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Akebia Therapeutics, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Caladrius Biosciences, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Allena Pharmaceuticals
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • KBP Biosciences Co., Ltd.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
  11. Section
    • References
    • Research Methodology
    • About Us and Sales Contact

*Browse 32 market data tables and 26 figures on "Global Chronic Kidney Disease Drugs Market” - forecast to 2030

View Our Licence Options

  • Need a Custom Report?

    We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

    Customize Now
  • Want to Buy a Report but have a Limited Budget?

    We help clients to procure the report or sections of the report at their budgeted price. Kindly click on the below to avail

    Request Discount
Logo

Reliability and Reputation

Esomar
Duns
Clutch
DMCA

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo